Zacks Investment Research lowered shares of Aratana Therapeutics (NASDAQ:PETX) from a buy rating to a hold rating in a report issued on Saturday, November 18th.
According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “
Other equities research analysts also recently issued reports about the stock. ValuEngine upgraded shares of Aratana Therapeutics from a sell rating to a hold rating in a research report on Tuesday, July 25th. Lake Street Capital dropped their price target on shares of Aratana Therapeutics from $15.00 to $10.00 and set a buy rating on the stock in a research report on Friday, August 25th. HC Wainwright began coverage on shares of Aratana Therapeutics in a research report on Friday, November 17th. They issued a buy rating and a $10.00 price target on the stock. BidaskClub downgraded shares of Aratana Therapeutics from a sell rating to a strong sell rating in a research report on Tuesday, August 8th. Finally, Jefferies Group set a $8.00 price objective on shares of Aratana Therapeutics and gave the company a buy rating in a research note on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $8.75.
Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.03. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The company had revenue of $6.16 million for the quarter, compared to the consensus estimate of $6.47 million. During the same period last year, the company posted ($0.38) EPS. The firm’s quarterly revenue was up 1440.0% compared to the same quarter last year. equities research analysts forecast that Aratana Therapeutics will post -1.03 earnings per share for the current fiscal year.
In related news, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $5.70, for a total value of $5,075,941.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $7.00, for a total transaction of $350,000.00. Following the completion of the transaction, the insider now directly owns 529,359 shares in the company, valued at $3,705,513. The disclosure for this sale can be found here. Insiders have sold a total of 1,127,032 shares of company stock worth $6,622,391 over the last ninety days. Insiders own 5.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PETX. Janus Henderson Group PLC purchased a new stake in Aratana Therapeutics during the second quarter valued at about $12,948,000. Broadfin Capital LLC increased its position in shares of Aratana Therapeutics by 40.3% during the second quarter. Broadfin Capital LLC now owns 5,184,942 shares of the biopharmaceutical company’s stock valued at $37,487,000 after buying an additional 1,489,500 shares during the period. Franklin Resources Inc. increased its position in shares of Aratana Therapeutics by 11.2% during the second quarter. Franklin Resources Inc. now owns 6,011,309 shares of the biopharmaceutical company’s stock valued at $43,462,000 after buying an additional 604,518 shares during the period. AWM Investment Company Inc. increased its position in shares of Aratana Therapeutics by 49.4% during the second quarter. AWM Investment Company Inc. now owns 1,587,620 shares of the biopharmaceutical company’s stock valued at $11,478,000 after buying an additional 525,000 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Aratana Therapeutics by 197.0% during the second quarter. Dimensional Fund Advisors LP now owns 380,895 shares of the biopharmaceutical company’s stock valued at $2,754,000 after buying an additional 252,655 shares during the period. 73.95% of the stock is currently owned by institutional investors and hedge funds.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.